PMID- 36326907
OWN - NLM
STAT- MEDLINE
DCOM- 20221206
LR  - 20221206
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
VI  - 30
IP  - 12
DP  - 2022 Dec
TI  - Management of adverse events related to first-generation tyrosine receptor kinase 
      inhibitors in adults: a narrative review.
PG  - 10471-10482
LID - 10.1007/s00520-022-07401-y [doi]
AB  - OBJECTIVE: The aim of this article is to conduct a literature review on 
      first-generation TRK inhibitors (TRKi), namely entrectinib and larotrectinib, to 
      describe the most common adverse events (AEs) and their management in adults. 
      METHODS: A search strategy was conducted in MEDLINE, EMBASE, and Google Scholar 
      using a list of predetermined keywords. Peer-reviewed articles written in English 
      and published through June 2021 were included. Articles covered included 
      randomized clinical trials and expert recommendations, as well as patent and 
      other types of reviews. RESULTS: The discussed AEs include weight gain and 
      withdrawal pain, as well as neuromuscular, central nervous system (dysesthesias 
      and peripheral sensory neuropathies, dizziness and ataxia, and dysgeusia), 
      gastrointestinal (nausea, vomiting, and diarrhea), and respiratory symptoms. 
      Additionally, several AEs encountered with entrectinib specifically (cognitive 
      and vision disorders, congestive heart failure, QTc elongation, and skeletal 
      fractures) are discussed. First, an overall mechanism of action explaining these 
      AEs is presented. Then, for each AE, incidence and severity are stated and 
      followed by practical management recommendations. While nearly all AEs were 
      reversible upon TRKi suspension, the proposed managements are mainly constituted 
      of pharmacological and non-pharmacological interventions. CONCLUSION: With the 
      estimated growth of gene sequencing in the coming years, it is foreseeable that 
      TRKi will take a larger position in the oncologic therapeutic arsenal. Therefore, 
      adequate management of AEs associated with TRKi in adults should be a prime 
      focus.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Martineau, Christine
AU  - Martineau C
AD  - Faculty of Pharmacy, Universite de Montreal, Montreal, Canada.
FAU - Turcotte, Maria-Kim
AU  - Turcotte MK
AD  - Faculty of Pharmacy, Universite de Montreal, Montreal, Canada.
FAU - Otis, Noemie
AU  - Otis N
AD  - Faculty of Pharmacy, Universite de Montreal, Montreal, Canada.
FAU - Provost, Frederic
AU  - Provost F
AD  - Faculty of Pharmacy, Universite de Montreal, Montreal, Canada.
FAU - Themens, Ludovic
AU  - Themens L
AD  - Faculty of Pharmacy, Universite de Montreal, Montreal, Canada.
FAU - Guay, Marie-Pascale
AU  - Guay MP
AD  - Department of Pharmacy, CIUSSS West-Central Montreal, Montreal, Canada.
FAU - Letarte, Nathalie
AU  - Letarte N
AD  - Faculty of Pharmacy, Universite de Montreal, Montreal, Canada.
AD  - Department of Pharmacy, Centre hospitalier de l'Universite de Montreal, 1050 
      Sanguinet, Montreal, H2X 0C1, Canada.
AD  - CHUM Research Center, CHUM, Montreal, Canada.
FAU - Adam, Jean-Philippe
AU  - Adam JP
AUID- ORCID: 0000-0002-7938-0944
AD  - Department of Pharmacy, Centre hospitalier de l'Universite de Montreal, 1050 
      Sanguinet, Montreal, H2X 0C1, Canada. jean-philippe.adam.chum@ssss.gouv.qc.ca.
AD  - CHUM Research Center, CHUM, Montreal, Canada. 
      jean-philippe.adam.chum@ssss.gouv.qc.ca.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221103
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - L5ORF0AN1I (entrectinib)
RN  - 0 (tyrosine receptor)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Protein Kinase Inhibitors/adverse effects
OTO - NOTNLM
OT  - Dizziness and ataxia
OT  - Management of adverse events
OT  - TRK inhibitors
OT  - Weight gain
OT  - Withdrawal-associated pain
EDAT- 2022/11/04 06:00
MHDA- 2022/12/06 06:00
CRDT- 2022/11/03 12:16
PHST- 2022/01/17 00:00 [received]
PHST- 2022/10/07 00:00 [accepted]
PHST- 2022/11/04 06:00 [pubmed]
PHST- 2022/12/06 06:00 [medline]
PHST- 2022/11/03 12:16 [entrez]
AID - 10.1007/s00520-022-07401-y [pii]
AID - 10.1007/s00520-022-07401-y [doi]
PST - ppublish
SO  - Support Care Cancer. 2022 Dec;30(12):10471-10482. doi: 
      10.1007/s00520-022-07401-y. Epub 2022 Nov 3.